The following are earned news media article, webinars and podcasts with contributions by CHC staff and member interviews and presentations. Framing DTC Rx Ad Ban: to convey courts, regulatory and legislative history that a DTC Rx advertising ban would ‘not be easily accomplished.’ Trump and RFK promised to ban D2C pharma advertising. Pharma is […]
Read more
Violet Aldaia has been elected as the new board chair of the Coalition for Healthcare Communication (CHC), a subsidiary of 4A’s, representing healthcare advertising, publishing and communications companies. She follows Jay Carter, former Executive Vice President of Business Development for AbelsonTaylor. Violet is President of Havas Life Chelsea, one of Havas Health Network’s flagship health […]
Read more
WASHINGTON, D.C., March 28, 2023 – James (Jim) Potter has been named the new Executive Director for the Coalition of Healthcare Communications (CHC), following the retirement of Jon Bigelow, and its acquisition by the American Association of Advertising Agencies (4A’s) in 2022. The acquisition was made to enable the CHC to expand their capabilities for […]
Read more
Sept. 27, 2021 – In the midst of public scrutiny regarding clinical trial transparency, the Food and Drug Administration (FDA) and the United Kingdom’s Health Research Agency (HRA) recently took actions that may indicate their increased willingness to more closely monitor clinical investigators who do not report trial results in a timely manner. “Pharma, researchers, […]
Read more
Sept. 17, 2018 – After 16 years with the Coalition for Healthcare Communication, John Kamp will be stepping down as Executive Director and Jon Bigelow has been named his successor. Kamp will continue his association with the Coalition as Washington Counsel. “Jon is exactly the right person at the right time to take the guiding […]
Read more
Jan. 27, 2017 – The FDA issued draft guidance last week that is designed to help medical product manufacturers understand how the agency evaluates product communications, including promotional materials, that present information not contained in the FDA-required labeling but that may be “consistent with” that labeling. “We are aware that firms have questions about how […]
Read more